Kestra Medical Technologies Q1 revenue beats estimates, raises FY revenue outlook
KMTS•Revenue growth drivers
The company said revenue growth was driven by expansion in the wearable cardioverter defibrillator, competitive share gains, new sales territories, and an improved revenue cycle.
- Market expansion - WCD market expansion, competitive share gains, and new sales territories drove revenue growth.
- In-network patients & revenue cycle - A higher mix of in-network patients and improved revenue cycle management contributed to revenue growth.
- Gross margin improvement - Volume leverage, a higher mix of in-network patients, and cost improvement programs drove gross margin expansion.
Q1 revenue beats estimates
Kestra Medical Technologies said fiscal first-quarter revenue grew 60% and beat analyst expectations. Adjusted EBITDA loss for fiscal Q1 also slightly beat consensus.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q1 Revenue | Beat | $30.97 mln | $29.008 mln (7 Analysts) |
| Q1 Loss Per Share | $0.75 | ||
| Q1 Adjusted EBITDA | Slight Beat* | -$24 mln | -$24.1 mln (5 Analysts) |
| Q1 Gross Profit | $17.5 mln | ||
| Q1 Income from Operations | -$37.66 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
